Michael Cruse - Mar 2, 2022 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (RPHM)

Role
Chief Operating Officer
Signature
/s/ Vineet R. Jindal, Attorney-in-Fact
Stock symbol
RPHM
Transactions as of
Mar 2, 2022
Transactions value $
$0
Form type
4
Date filed
3/4/2022, 08:51 PM
Previous filing
Dec 14, 2021
Next filing
Aug 31, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RPHM Stock option (right to buy) Award $0 +25K $0.00 25K Mar 2, 2022 Common Stock 25K $4.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares vest in a series of 48 successive equal monthly installments measured from March 2, 2022, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.